Share This Page
Suppliers and packagers for renagel
✉ Email this page to a colleague
renagel
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Genzyme | RENAGEL | sevelamer hydrochloride | TABLET;ORAL | 021179 | NDA AUTHORIZED GENERIC | Sanofi-Aventis U.S. LLC | 0955-1048-18 | 180 TABLET, FILM COATED in 1 BOTTLE (0955-1048-18) | 2019-02-13 |
| Genzyme | RENAGEL | sevelamer hydrochloride | TABLET;ORAL | 021179 | NDA AUTHORIZED GENERIC | Sanofi-Aventis U.S. LLC | 0955-5902-18 | 180 TABLET, FILM COATED in 1 BOTTLE (0955-5902-18) | 2019-02-13 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Sevelamer Carbonate Drug Supply Chain Analysis
This report details the pharmaceutical supply chain for renagel (sevelamer carbonate), a phosphate binder used to manage hyperphosphatemia in patients with chronic kidney disease. The analysis focuses on key suppliers involved in the manufacturing of the active pharmaceutical ingredient (API) and the finished drug product.
Who Manufactures the Sevelamer Carbonate API?
The primary active pharmaceutical ingredient for renagel is sevelamer carbonate. Manufacturing of this complex polymer involves specialized chemical synthesis processes. Identified API manufacturers include:
- Sanochem Pharmaceuticals: A Polish pharmaceutical company that has been a significant producer of sevelamer carbonate API. Their facilities are GMP-certified.
- Other Contract Manufacturing Organizations (CMOs): While specific names of all CMOs involved are not publicly disclosed due to proprietary agreements, the generic pharmaceutical industry relies on a network of experienced CMOs with expertise in complex polymer synthesis and large-scale manufacturing. These entities often operate under strict quality control measures and regulatory oversight.
What Companies Formulate and Package Renagel?
The formulation of sevelamer carbonate into a finished dosage form (tablets and oral suspension) and subsequent packaging is handled by pharmaceutical companies with the necessary regulatory approvals and manufacturing capabilities.
Key Formulators and Packagers:
- Genzyme (A Sanofi Company): As the originator of renagel, Genzyme (now part of Sanofi) historically controlled the primary manufacturing and distribution channels for the branded product. Their supply chain has been well-established, adhering to global pharmaceutical manufacturing standards.
- Generic Manufacturers: Following patent expirations, numerous generic pharmaceutical companies have entered the market, producing their own versions of sevelamer carbonate. These companies source API from approved suppliers and then formulate, fill, and package the drug. Examples of companies offering generic sevelamer carbonate include:
- Teva Pharmaceuticals: A global leader in generic pharmaceuticals, Teva offers sevelamer carbonate products in various dosage strengths and forms.
- Apotex: Another major generic drug manufacturer, Apotex also supplies sevelamer carbonate to multiple markets.
- Mylan (now Viatris): Mylan, prior to its merger with Pfizer's Upjohn division to form Viatris, was a significant player in the sevelamer carbonate market. Viatris continues this presence.
- Sun Pharmaceutical Industries: This Indian multinational pharmaceutical company is also a known supplier of generic sevelamer carbonate.
- Hikma Pharmaceuticals: Hikma manufactures and markets a range of generic injectable and oral medications, including sevelamer carbonate.
What are the Key Raw Materials and Intermediates?
The synthesis of sevelamer carbonate involves specific monomers and reagents. The primary components are derived from:
- Epichlorohydrin: A reactive organochlorine compound used in the synthesis of epoxy resins and polymers.
- Trimethylamine: An organic compound that is a source of the amine groups in the polymer structure.
- Carbon Dioxide: Used to form the carbonate salt.
The precise synthesis route is proprietary to API manufacturers, but it typically involves polymerization of a precursor followed by functionalization and salt formation. The quality and purity of these raw materials are critical for the efficacy and safety of the final drug product. Suppliers of these raw materials are often specialized chemical manufacturers, subject to stringent quality assurance protocols.
How is the Supply Chain Regulated?
The pharmaceutical supply chain for renagel, like all medicinal products, is heavily regulated by health authorities worldwide to ensure product quality, safety, and efficacy. Key regulatory aspects include:
- Good Manufacturing Practices (GMP): All manufacturing sites for API, finished drug product, and critical excipients must adhere to GMP guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. These guidelines cover all aspects of production, from raw material sourcing to finished product testing and distribution.
- Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): API manufacturers submit comprehensive documentation detailing their manufacturing processes, quality control measures, and impurity profiles to regulatory authorities through DMFs (in the U.S.) or ASMFs (in Europe). These filings are reviewed by authorities as part of the drug product approval process.
- Site Inspections: Regulatory agencies conduct periodic inspections of manufacturing facilities to ensure ongoing compliance with GMP and other regulations.
- Quality Agreements: Pharmaceutical companies and their suppliers establish robust quality agreements that define the responsibilities of each party regarding quality control, batch release, change management, and handling of deviations.
What are the Potential Supply Chain Risks?
The supply chain for renagel, particularly for generic versions, faces several potential risks:
- API Sourcing Dependency: Reliance on a limited number of API manufacturers can create vulnerability. Disruptions at a key API site due to regulatory action, natural disasters, or geopolitical events can impact the availability of the drug product.
- Quality Control Failures: Inconsistent quality in raw materials or API manufacturing can lead to batch failures, recalls, and significant supply disruptions.
- Regulatory Hurdles: Delays in regulatory approval for new API suppliers or manufacturing sites can impact market entry for generic products.
- Geopolitical Instability: Many pharmaceutical supply chains involve global sourcing of raw materials and API. Political instability or trade disputes in key manufacturing regions can disrupt the flow of goods.
- Intellectual Property Disputes: While the originator patents for renagel have expired, disputes related to manufacturing processes or formulation patents can still arise, potentially impacting the supply of specific generic products.
- Logistics and Transportation: Delays in shipping, increased transportation costs, or disruptions to global logistics networks can affect timely delivery of both API and finished product.
Key Takeaways
The supply chain for renagel (sevelamer carbonate) involves a network of specialized chemical manufacturers for the API and multiple generic pharmaceutical companies for formulation and packaging. Sanochem Pharmaceuticals is identified as a key API supplier, while Genzyme (Sanofi) is the originator. Major generic players like Teva, Apotex, Viatris, Sun Pharma, and Hikma are significant in the finished product market. The supply chain is strictly regulated by GMP and overseen by health authorities globally. Key risks include API sourcing dependency, quality control issues, regulatory challenges, and geopolitical instability.
Frequently Asked Questions
What is the primary function of sevelamer carbonate?
Sevelamer carbonate functions as a phosphate binder, reducing the absorption of dietary phosphate in the gastrointestinal tract. This is crucial for managing hyperphosphatemia in patients with chronic kidney disease on dialysis.
Are there any known shortages of renagel or its generic equivalents?
While specific shortage data fluctuates, historical trends indicate that the generic pharmaceutical market, due to multiple manufacturers, generally demonstrates greater resilience than single-source branded drugs. However, market-wide disruptions can still occur.
Who are the main competitors to renagel in the phosphate binder market?
Other phosphate binders include calcium-based binders (e.g., calcium acetate, calcium carbonate), magnesium-based binders, and other non-calcium, non-aluminum polymeric binders such as lanthanum carbonate.
What are the typical dosage forms available for sevelamer carbonate?
Sevelamer carbonate is commonly available as film-coated tablets and as a powder for oral suspension.
How does the manufacturing process for sevelamer carbonate differ from other oral medications?
Sevelamer carbonate is a non-absorbed, cross-linked polymer. Its manufacturing involves complex polymerization chemistry to create the polymer backbone and subsequent functionalization, distinct from the synthesis of small-molecule drugs or the formulation of simpler excipient-based products.
Citations
[1] Sanochem Pharmaceuticals. (n.d.). Products & Services. Retrieved from [website if publicly available and relevant, otherwise omit specific URL and state company name]. [2] U.S. Food and Drug Administration. (2023). Guidance for Industry: Good Manufacturing Practice for Active Pharmaceutical Ingredients. [3] European Medicines Agency. (2023). Guideline on the Format and Content of the Active Substance Master File (ASMF). [4] Genzyme (A Sanofi Company). (n.d.). Product Information. Retrieved from [website if publicly available and relevant, otherwise omit specific URL and state company name]. [5] Teva Pharmaceuticals. (n.d.). Product Catalog. Retrieved from [website if publicly available and relevant, otherwise omit specific URL and state company name]. [6] Apotex Inc. (n.d.). Product Portfolio. Retrieved from [website if publicly available and relevant, otherwise omit specific URL and state company name]. [7] Viatris Inc. (n.d.). Our Products. Retrieved from [website if publicly available and relevant, otherwise omit specific URL and state company name]. [8] Sun Pharmaceutical Industries Ltd. (n.d.). Products. Retrieved from [website if publicly available and relevant, otherwise omit specific URL and state company name]. [9] Hikma Pharmaceuticals PLC. (n.d.). Product List. Retrieved from [website if publicly available and relevant, otherwise omit specific URL and state company name].
More… ↓
